DEF: Athira Pharma Seeks Stockholder Approval for Reverse Stock Split and Share Reduction to Regain Nasdaq Compliance

Athira Pharma is asking stockholders to approve a reverse stock split and reduction in authorized shares to meet Nasdaq's minimum bid price requirement and potentially improve stock marketability.

Summary

• Athira Pharma is holding its 2025 annual meeting of stockholders on May 29, 2025, virtually.
• The meeting will address the election of three Class II directors, ratification of Ernst & Young LLP as the independent accounting firm, and approval of amendments to the company's certificate of incorporation.
• The proposed amendments include a reverse stock split at a ratio of 5:1, 10:1, 15:1, or 20:1, to be determined by the board, and a reduction in the total number of authorized shares of common stock.
• The reverse stock split is intended to increase the company's stock price to meet Nasdaq's minimum bid price requirement of $1.00 per share.
• The company received a notice from Nasdaq on October 16, 2024, indicating non-compliance with the minimum bid price requirement.
• The reduction in authorized shares is designed to maintain the proportion of unissued shares and satisfy stockholder voting policies.
• The board of directors recommends voting for all proposals.
• As of April 4, 2025, there were 39,042,445 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting factual information about the upcoming shareholder meeting and proposals. The reverse stock split is a concerning sign, but the company is taking steps to address the issue.

Positives

• The proposed reverse stock split aims to increase the per-share market price of the common stock, potentially improving its marketability and attracting a broader range of investors.
• Reducing the number of authorized shares may satisfy the voting policies of certain stockholders and reduce certain costs.
• The company is taking steps to address Nasdaq's minimum bid price requirement, which could prevent delisting and maintain stock liquidity.

Negatives

• There is no guarantee that the reverse stock split will increase the stock price or improve marketability.
• The reverse stock split may decrease the liquidity of the common stock and result in higher transaction costs.
• The company's stock price has been below $1.00, leading to a Nasdaq non-compliance notice.

Risks

• The reverse stock split may not result in a proportionate increase in the stock price, and the total market capitalization may decrease.
• Other factors, such as clinical trial results and market conditions, may adversely affect the stock price.
• The liquidity of the common stock may be negatively impacted by the reverse stock split.
• The company may not be able to regain compliance with Nasdaq listing requirements, leading to delisting.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements and improve the marketability of its common stock through the proposed reverse stock split and share reduction.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. The success of a reverse stock split depends on various factors, including the company's underlying financial health and market perception.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges have implemented reverse stock splits to maintain their listing on exchanges like Nasdaq.
• Comparable companies that have recently undertaken reverse stock splits include XOMA Corporation and Vaxcyte, Inc.
• The effectiveness of these splits varies, with some companies experiencing sustained price increases while others see only a temporary boost.

Related Party Transactions

• The company has entered into an investors rights agreement with certain stockholders, including Dr. Litton, Mark Worthington, Fluke Capital Management, L.P., and Perceptive Life Sciences Master Fund Ltd.

Stakeholder Impact

• The reverse stock split could impact shareholders by potentially increasing the stock price, but also by potentially decreasing liquidity and increasing transaction costs.
• Employees may be affected by the company's efforts to regain compliance with Nasdaq listing requirements.
• The company's ability to attract investors and raise capital could be affected by the reverse stock split.

Next Steps

• Stockholders will vote on the proposals at the annual meeting on May 29, 2025.
• The board of directors will determine the final reverse stock split ratio, if approved.
• The company will file a Certificate of Amendment with the Delaware Secretary of State to effect the reverse stock split and share reduction, if approved and implemented.

Key Dates

Keywords

reverse stock split, authorized shares, Nasdaq, compliance, proxy statement, directors, stockholders, Athira Pharma, meeting, voting